Cardiology Flashcards
Systolic Heart Failure
Heart Failure Reduced Ejection Fraction
- LVEF
Diastolic Heart Failure
(Heart Failure Preserved Ejection Fraction
LVEF >40%
Exclude IHD and Valvular Disease
NYHA Classification
I - No symptoms, even during exercise
II - Reduced physical capacity during medium exercise
III - Severely reduced physical capacity
during slight exercise, but asymptomatic at rest
IV - Symptomatic at rest
Ix of HF
Bloods
- FBE, UEC, LFTs, BNP, TFT, Fe Studies
Cardiac adaptations to HF
- Cardiomegaly (same %, of a bigger volume)
- 2ndary LVH
- Valvular disfunction due to dilation
Management of Sys HF
Mx # Non-Pharmacologica Therapy - Na, Diet, Smoking, Exerc # Initial Pharmacological Therapy 1. Low pressure/No oedema - Inotropes +/- fluids 2. Low pressure/ Oedema - Inotropes 3. High Pressure/No Oedema - ACE/ARB 4. High Pressure/Oedema - ACE/ARB + diuretics
CHADS2VASc
C - Congestive heart failure - 1 H - Hypertension - 1 A2 - Age ≥75 years - 2 D - Diabetes Mellitus - 1 S2 - Prior Stroke or TIA - 2 V - Vascular disease PVD, AMI, aortic plaque - 1 A - Age 65–74 years - 1 Sc - Sex category (Female) - 1
Pharmacological management of HF
- Diuretics
- ACEi/ARB
- Beta Blocker - Best NNT
- Ivabradine
- Hydralazine/nitrates
Diuretics - Heart Failure
Frusemide
- increased survival in APO
# Thiazide
- Good symptom relief (no good long/short term data)
# Aldactone
- Increased survival - good long term data
- RALES Trial 30% better survival
ACEi/ARB - Heart Failure
# ACE - Survival benefit (~7%) - Dose that can be tolerated (K/BP) # ARB - Similar improvement to ACE - Used if intolerance to ACE
No benefit in Diastolic function
Beta Blockers - Heart Failure
Survival Benefit - highest dose tolerated
# Cardio selective - no head to head studies (~34%)
- Carvidolol
- Bisoprolol
- Metoprolol XL
Ivabradine - Heart Failure
# SHIFT Study - 18% Decrease in major outcome - admission/CV death # Mechanism - Decrease HR - (funny channels) - Neutral inotrope capacity - Doesn't decrease BP # Criteria - NYHA II, III - EF77 - Sinus
Hydralazine/Nitrates - Heart Failure
- Consider if high BP/poor renal function
HF Drugs to Avoid
- NSAIDs
- Anti-arrhythmic
- Ca Channel blockers
ICD in HF
- LVEF
Neprilysin & Valsartan - Heart Failure
Paradigm HF Trial
- 20% Decrease in death
- additional therapy
- Superior to ACE
AF
2 Components # Substrate abnormalities - LA stretch - Increased LA pressure - LA fibrosis - Autonomic Abnormalities # Electrical triggers
Indications for ICD
Class I
- Symptomatic Sinus bradycardia (
Vibrates
- Increase lipoprotein lipase activity - decrease LDL, increase HDL and importantly decrease Trig
HCM
Key Finding in HCM
- Hypertrophy and diastolic dysfunction
- Dynamic pressure gradient
- 1st Degree relative screening – 5yrs screening
ICD in HCM
- Unexplained Syncope
- Abnormal BP response to exercise
- > 30mm ventricular wall thickness
- Non-Sustained VT
- Cardiac MRI >15% gallium uptake - Fibrosis
- CAD
Prolonged QT (congenital)
- Betablocker (not sotalol)
- ICD - Indications
Acute Management of Chest Pain
- Aspirin
- O2 if
Avoid Study
- O2 if Stats
STEMI
- Dx
- Solely by ECG - Mx
# PCI
# Thrombolytic
3.
Long QT Syndrome
Delayed/abnormal polarisation/repolarisation
Dx
- on routine ECG or following family screening
- Need to look at corrected (rate dependant)
Management
- avoid drugs which prolong the QT interval and other precipitants if appropriate (e.g. Strenuous exercise)
beta-blockers***
- implantable cardioverter defibrillators in high risk cases
*the usual mechanism by which drugs prolong the QT interval is blockage of potassium channels.
**a non-sedating antihistamine and classic cause of prolonged QT in a patient, especially if also taking P450 enzyme inhibitor, e.g. Patient with a cold takes terfenadine and erythromycin at the same time
Types of long QT Sydromes - Genetic
- Long QT1 - usually associated with exertional syncope, often swimming
- Long QT2 - often associated with syncope occurring following emotional stress, exercise or auditory stimuli
- Long QT3 - events often occur at night or at rest
sudden cardiac death
Enzymes and AMI
1st - Myoglobin - 1-2 hours 2nd - CK-MB - 2-6 hours 3rd - CK - 4-8 hours 4th - Trop T 5th - AST 6th - LDH
CK-MB is useful to look for reinfarction as it returns to normal after 2-3 days (troponin T remains elevated for up to 10 days)
Hypertrophic obstructive cardiomyopathy (HOCM)
- HOCM is the most common cause of death in young people
- is an autosomal dominant disorder of muscle tissue caused by defects in the genes encoding contractile proteins.
- The most common defects involve a mutation in the gene encoding β-myosin heavy chain protein or myosin binding protein C.
- The estimated prevalence is 1 in 500
Infective Endocarditis
- Streptococcus viridans (most common cause - 40-50%).
- Staphylococcus epidermidis (especially prosthetic valves)
- Staphylococcus aureus (especially acute presentation, IVDUs)
- Streptococcus bovis is associated with colorectal cancer
- non-infective: systemic lupus erythematosus (Libman-Sacks), malignancy: marantic endocarditis
Agents with proven efficacy in the pharmacological cardioversion of atrial fibrillation
- amiodarone
- flecainide (if no structural heart disease)
- others (less commonly used in UK): quinidine, dofetilide, ibutilide, propafenone
Congenital heart disease
- cyanotic: TGA most common at birth, Fallot’s most common overall
- acyanotic: VSD most common cause
Aortic dissection
- type A - ascending aorta - control BP(IV labetalol/betablocker) + surgery
- type B - descending aorta - control BP(IV labetalol/beta blocker)
Management of AF
- Rate Control
- 1st beta blockers preferable to digoxin
- 2nd Ca Channel Blockers
- 3rd Digoxin not used 1st line unless cardiac failure - Rhythm Control
- if >48hrs - Toe DCR/ameoderone
- if <48hrs - DCR/ameroderone
Acute Pericarditis causes
viral infections (Coxsackie)
tuberculosis
uraemia (causes ‘fibrinous’ pericarditis)
trauma
post-myocardial infarction, Dressler’s syndrome
connective tissue disease
hypothyroidism
Acute Pericarditis Dx
- Chest pain relieved by sitting forward
- Chest pain relieved by exhaling
ECG changes - widespread ‘saddle-shaped’ ST elevation
- PR depression: most specific ECG marker for pericarditis
Myocardial infarction: secondary prevention
All patients should be offered the following drugs:
- dual antiplatelet therapy (aspirin plus a second antiplatelet agent) - event without stent
- ACE inhibitor
- beta-blocker
- statin
AMI regions
http://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd519b.png